VEGFA and cerebral infarction: Spontaneous adverse event reporting data, derived from real-world clinical practice and employed by regulatory authorities for pharmacovigilance purposes, are well suited for the analysis of rare adverse events, such as cerebral infarction associated with anti-VEGF agents.